Clinical Trials Browser

Phase 2/3 × Epstein-Barr Virus Infections × 30 days × Clear all

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

Phase 2/3 Active not recruiting

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections